Laguna Bio unveiled a living‑drug platform built from a highly attenuated Listeria monocytogenes strain engineered to elicit multifactorial immune responses and activate rare gamma delta T cells. Founders Jonathan Kotula, Dan Portnoy and Russell Carrington described a programmatic strategy that combines microbial biotherapeutics with principles from cell and immune therapies. The company plans first-in-human testing of its lead Listeria strain in pediatric leukemia with the aim of durable immune control. Laguna’s approach departs from single‑target modalities by leveraging pathogen‑native immune engagement to generate broad antitumor activity; safety, dosing and controllability will be focal endpoints in early clinical trials.